Literature DB >> 14715655

A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis.

Mark Schneider1, Michael Nesheim.   

Abstract

Previous work using soluble fibrin surrogates or very dilute fibrin indicate that inhibition of plasmin by antiplasmin is attenuated by fibrin surrogates; however, this phenomenon has not been quantified within intact fibrin clots. Therefore, a novel system was designed to measure plasmin inhibition by antiplasmin in real time within an intact clot during fibrinolysis. This was accomplished by including the plasmin substrate S2251 and a recombinant fluorescent derivative of plasminogen (S741C-fluorescein) into clots formed from purified components. Steady state plasmin levels were estimated from the rates of S2251 hydrolysis, the rates of plasminogen activation were estimated by fluorescence decrease over time, and residual antiplasmin was deduced from residual fluorescence. From these measurements, the second order rate constant could be inferred at any time during fibrinolysis. Immediately after clot formation, the rate constant for inhibition decreased 3-fold from 9.6 x 10(6) m(-1) s(-1) measured in a soluble buffer system to 3.2 x 10(6) m(-1) s(-1) in an intact fibrin clot. As the clot continued to lyse, the rate constant for inhibition continued to decrease by 38-fold at maximum. To determine whether this protection was the result of plasmin exposure of carboxyl-terminal lysine residues, clots were formed in the presence of activated thrombin-activatable fibrinolysis inhibitor (TAFIa). In the presence of TAFIa, the initial protective effect associated with clot formation occurred; however, the secondary protective effect associated with lysine residue exposure was delayed in a TAFIa concentration-dependent manner. This latter effect represents another mechanism whereby TAFIa attenuates fibrinolysis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14715655     DOI: 10.1074/jbc.M313164200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  A high affinity interaction of plasminogen with fibrin is not essential for efficient activation by tissue-type plasminogen activator.

Authors:  Paul Y Kim; Long D Tieu; Alan R Stafford; James C Fredenburgh; Jeffrey I Weitz
Journal:  J Biol Chem       Date:  2011-12-20       Impact factor: 5.157

2.  Reprogrammed streptokinases develop fibrin-targeting and dissolve blood clots with more potency than tissue plasminogen activator.

Authors:  I Y Sazonova; R A McNamee; A K Houng; S M King; L Hedstrom; G L Reed
Journal:  J Thromb Haemost       Date:  2009-06-30       Impact factor: 5.824

3.  Reduced plasminogen binding and delayed activation render γ'-fibrin more resistant to lysis than γA-fibrin.

Authors:  Paul Y Kim; Trang T Vu; Beverly A Leslie; Alan R Stafford; James C Fredenburgh; Jeffrey I Weitz
Journal:  J Biol Chem       Date:  2014-08-15       Impact factor: 5.157

4.  In vitro evaluation of clot quality and stability in a model of severe thrombocytopenia: effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor.

Authors:  Boris Shenkman; Yulia Einav; Tami Livnat; Ivan Budnik; Uriel Martinowitz
Journal:  Blood Transfus       Date:  2013-11-29       Impact factor: 3.443

Review 5.  Fibrinolysis and the control of blood coagulation.

Authors:  John C Chapin; Katherine A Hajjar
Journal:  Blood Rev       Date:  2014-09-16       Impact factor: 8.250

6.  Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation.

Authors:  Masahiro Ieko; Mika Yoshida; Sumiyoshi Naito; Toru Nakabayashi; Kaoru Kanazawa; Kazuhiro Mizukami; Masaya Mukai; Tatsuya Atsumi; Takao Koike
Journal:  Int J Hematol       Date:  2010-05-21       Impact factor: 2.490

Review 7.  Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?

Authors:  J L Willemse; E Heylen; M E Nesheim; D F Hendriks
Journal:  J Thromb Haemost       Date:  2009-08-28       Impact factor: 5.824

8.  Activated thrombin-activatable fibrinolysis inhibitor is generated in vivo at levels that can substantially affect fibrinolysis in chimpanzees in response to thrombin generation.

Authors:  P Y G Kim; P Y Kim; H Hoogendorn; A R Giles; M E Nesheim
Journal:  J Thromb Haemost       Date:  2008-07-04       Impact factor: 5.824

Review 9.  Plasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis?

Authors:  Be'eri Niego; Robert L Medcalf
Journal:  J Cereb Blood Flow Metab       Date:  2014-06-04       Impact factor: 6.200

10.  A Case of Unexplained Cerebral Sinus Thrombosis in a 22-Year-Old Obese Caucasian Woman.

Authors:  Jansen N Seheult; Irina Chibisov
Journal:  Lab Med       Date:  2016-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.